Abstract
Studies of dipeptidyl peptidase-4 inhibitors (DPP-4i) report heterogeneous effects on endothelial function in patients with type 2 diabetes. This study assessed the effects of the DPP-4i linagliptin (LINA) vs the sulfonylurea glimepiride (GLIM) and placebo (PBO) on measures of macro- and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
